CN105274082B - A kind of synthesis penicillin G acylase mutant and its application in preparing Amoxicillin - Google Patents
A kind of synthesis penicillin G acylase mutant and its application in preparing Amoxicillin Download PDFInfo
- Publication number
- CN105274082B CN105274082B CN201510736957.7A CN201510736957A CN105274082B CN 105274082 B CN105274082 B CN 105274082B CN 201510736957 A CN201510736957 A CN 201510736957A CN 105274082 B CN105274082 B CN 105274082B
- Authority
- CN
- China
- Prior art keywords
- amino acids
- sport
- subunits
- subunit
- penicillin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010073038 Penicillin Amidase Proteins 0.000 title claims abstract description 49
- 229960003022 amoxicillin Drugs 0.000 title claims abstract description 40
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 title claims abstract description 37
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 238000003786 synthesis reaction Methods 0.000 title abstract description 41
- 230000015572 biosynthetic process Effects 0.000 title abstract description 40
- 102000004190 Enzymes Human genes 0.000 claims abstract description 90
- 108090000790 Enzymes Proteins 0.000 claims abstract description 90
- 230000035772 mutation Effects 0.000 claims abstract description 53
- 238000006243 chemical reaction Methods 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 38
- 241001673062 Achromobacter xylosoxidans Species 0.000 claims abstract description 21
- 230000008569 process Effects 0.000 claims abstract description 13
- 239000007787 solid Substances 0.000 claims abstract description 11
- 239000000758 substrate Substances 0.000 claims abstract description 8
- 235000021050 feed intake Nutrition 0.000 claims abstract description 3
- 150000001413 amino acids Chemical class 0.000 claims description 70
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- NGHVIOIJCVXTGV-ALEPSDHESA-N 6-aminopenicillanic acid Chemical compound [O-]C(=O)[C@H]1C(C)(C)S[C@@H]2[C@H]([NH3+])C(=O)N21 NGHVIOIJCVXTGV-ALEPSDHESA-N 0.000 claims description 15
- NGHVIOIJCVXTGV-UHFFFAOYSA-N 6beta-amino-penicillanic acid Natural products OC(=O)C1C(C)(C)SC2C(N)C(=O)N21 NGHVIOIJCVXTGV-UHFFFAOYSA-N 0.000 claims description 15
- 229940056360 penicillin g Drugs 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229940024554 amdinocillin Drugs 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N chembl530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- -1 F 310 amino acids Chemical class 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 27
- 230000007062 hydrolysis Effects 0.000 abstract description 23
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 23
- 108010093096 Immobilized Enzymes Proteins 0.000 abstract description 6
- 238000013461 design Methods 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000009418 renovation Methods 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 230000000694 effects Effects 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000005215 recombination Methods 0.000 description 7
- 230000006798 recombination Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 230000002194 synthesizing effect Effects 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000019371 penicillin G benzathine Nutrition 0.000 description 5
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000002585 base Substances 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- UXOLDCOJRAMLTQ-UHFFFAOYSA-N ethyl 2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(Cl)=NO UXOLDCOJRAMLTQ-UHFFFAOYSA-N 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 3
- NVIAYEIXYQCDAN-CLZZGJSISA-N 7beta-aminodeacetoxycephalosporanic acid Chemical compound S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](N)[C@@H]12 NVIAYEIXYQCDAN-CLZZGJSISA-N 0.000 description 3
- 241000590020 Achromobacter Species 0.000 description 3
- 108700023418 Amidases Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000194107 Bacillus megaterium Species 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 102000005922 amidase Human genes 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 229940106164 cephalexin Drugs 0.000 description 3
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 230000009465 prokaryotic expression Effects 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000002132 β-lactam antibiotic Substances 0.000 description 3
- 229940124586 β-lactam antibiotics Drugs 0.000 description 3
- 241000588813 Alcaligenes faecalis Species 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 101100346764 Mus musculus Mtln gene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229960004841 cefadroxil Drugs 0.000 description 2
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 238000002742 combinatorial mutagenesis Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 229960003424 phenylacetic acid Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FBVVGPMIPAZFAW-RZVRUWJTSA-N (2S)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.OC(=O)[C@@H]1CCCN1 FBVVGPMIPAZFAW-RZVRUWJTSA-N 0.000 description 1
- KUNFMZSTKSLIEY-GRHHLOCNSA-N (2s)-2-azanyl-3-phenyl-propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=CC=C1 KUNFMZSTKSLIEY-GRHHLOCNSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- NFQAIWOMJQWGSS-UHFFFAOYSA-N 3-amino-3-methylbutanoic acid Chemical compound CC(C)(N)CC(O)=O NFQAIWOMJQWGSS-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241001665942 Achromobacter sp. CCM 4824 Species 0.000 description 1
- DEFJQIDDEAULHB-UHFFFAOYSA-N Alanyl-alanine Chemical compound CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 241000589565 Flavobacterium Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 241000588773 Kluyvera cryocrescens Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 101000574352 Mus musculus Protein phosphatase 1 regulatory subunit 17 Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000588777 Providencia rettgeri Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229940005347 alcaligenes faecalis Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 108010042238 caspase-activated deoxyribonuclease Proteins 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- DKLZRLRMFNWRFB-UHFFFAOYSA-N methyl 2-(4-hydroxyanilino)acetate Chemical compound COC(=O)CNC1=CC=C(O)C=C1 DKLZRLRMFNWRFB-UHFFFAOYSA-N 0.000 description 1
- OUZXBEXZNBFNDM-UHFFFAOYSA-N methyl 2-(hydroxyamino)-2-phenylacetate Chemical compound COC(=O)C(NO)C1=CC=CC=C1 OUZXBEXZNBFNDM-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000003279 phenylacetic acid Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical class [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010045269 tryptophyltryptophan Proteins 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01011—Penicillin amidase (3.5.1.11), i.e. penicillin-amidohydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/84—Penicillin amidase (3.5.1.11)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P37/00—Preparation of compounds having a 4-thia-1-azabicyclo [3.2.0] heptane ring system, e.g. penicillin
- C12P37/04—Preparation of compounds having a 4-thia-1-azabicyclo [3.2.0] heptane ring system, e.g. penicillin by acylation of the substituent in the 6 position
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The present invention provides a kind of synthesis penicillin G acylase mutant and its applications in preparing Amoxicillin.Half design and rational of fixed point saturation mutation technology and the enzyme engineering renovation technique of orthogenesis is combined to be mutated the penicillin G acylase in Achromobacter xylosoxidans source by CAD; it is lower to obtain hydrolysis vigor; synthesis of dynamic is more preferable; synthesize that hydrolysis ratio (S/H) higher, acid resistance be stronger and the better penicillin G acylase mutant of stability; can be more effective, rapidly catalyze and synthesize Amoxicillin.The 4 immobilized enzyme hydrolysis vigor of mutant SPGA that the present invention obtains has dropped 8.7 times, synthesis of dynamic improves 5.6 times, S/H values improve 8 times, 60min keeps 79% vigor under the conditions of pH2.0, catalyzes and synthesizes Amoxicillin using 10 DEG C or 20 DEG C of solid process, the wherein 6 direct solids of APA and D HPM of substrate feed intake without dissolving, pH is reacted without control, 300 batches or more can be used continuously 99% or more in substrate conversion efficiency, have good operational stability.
Description
Technical field
The invention belongs to genetic engineering and enzyme engineering field, it is prominent that particular content is related to a kind of synthesis penicillin G acylase
The application of variant and the mutant immobilised enzymes in preparing Amoxicillin production.
Background technology
Amoxicillin (Amoxicillin) is a kind of most common penicillins wide spectrum beta-lactam antibiotic.Mesh
Before, the industrial method for producing Amoxicillin has two methods of chemical synthesis and enzyme process, and enzyme process is relatively low with cost, technique is simple
Singly, the advantages that green non-pollution and reaction condition are mild, therefore, is paid more and more attention.
Penicillin G acylase (penicillin G acylase, PGA, EC 3.5.1.11), is catalyzed in acid condition
Parent nucleus (6-APA or 7-ADCA) and side chain synthesis beta-lactam antibiotic are (such as:Amoxicillin, ampicillin, cefalexin
With cefadroxil etc.);Hydrolyzing penicillin G prepares 6-APA under alkaline condition or hydrolysis Cephalosporin G prepares 7-ADCA.
The source of the penicillin G acylase of wild type is very extensive, is acylated currently, having filtered out numerous production benzyl penicillins
The microorganism of enzyme simultaneously by its encoding gene clone come, as escherichia coli (Escherichia coli ATCC 11105),
Flavobacterium (Flavobacterium sp.650), bacillus megaterium (Bacillus megaterium), Bacillus foecalis alkaligenes
(Alcaligenes faecalis), Achromobacter xylosoxidans (Achromobacter xylosoxidans), achromobacter
Belong to (Achromobacter sp.CCM 4824), thermophilic grams of citric acid Lv Woer Salmonellas (Kluyvera citrophila), Lei Shi
Providence (Providencia rettgeri) etc..
Currently, being found during Production by Enzymes Amoxicillin, wild type Penicillin G acylases hydrolysing activity is high, closes
The shortcomings of Viability low, synthesis hydrolysis is smaller than (S/H), side chain consumption is high, the acid resistance of especially enzyme is weak, stability is poor, cause
The cost that enzyme process prepares Amoxicillin is higher.
With the development of genetic engineering and protein engineering techniques, domestic and international researcher is with design and rational, half rationality
The report that the means such as design and nonideal explosives carry out mutation transformation to the synthesis performance of penicillin G acylase has very much, such as
In Chinese patent CN101177688, Huang He, huge rock etc. are with homologous modeling and site-directed mutagenesis technique to bacillus megaterium PGA
144 sites α on tyrosine sport 24 site of arginine and β valine mutation be phenylalanine, obtain mutant
Synthesis performance, S/H ratios and the 7-ADCA conversion ratios of enzyme all improve a lot;In Chinese patent CN 103275960, Lai Hong
Star, Xiao Yongjun etc. to achromobacter penicillin G acylase proenzyme engineer and express, obtain one kind can synthesize Ah
The PGA of Amdinocillin, enzyme activity have reached 28000U/L (composing type) or 35000U/L (induction type);Cheng Tianfan (Zhejiang University
Master thesis, 2005) the mixed group of DNA families is carried out in combination with inhibition zone screening technique to 5 kinds of wild type PGA genes, it obtains
Obtained synthesis performance and PGA mutant that S/H values all significantly improve;Senwen Deng, Erzheng Su etc. (Journal of Biotechnology,Volume 199, 10April 2015, Pages 62-68) and utilize albumen renovation technique to produce alkali bar to excrement
Bacterium PGA is transformed, and the phenylalanine on its 24 site β is sported glycine, alanine, serine or proline, wherein F
The effect of β 24G synthesis ampicillin is best;International patent application WO2010/072765 is reported to E.coli ATCC 11105
The PGA in source is transformed, and is carried out to its A3, A77, A90, A144, A192, B24, B109, B148, B313, B460 and B488
Single-point or combinatorial mutagenesis obtain synthesis performance and multiple mutant that S/H values greatly improve;European patent EP 0961825 is reported
With protein engineering techniques alanine or leucine are sported to the phenylalanine on 24 sites β of Escherichia coli PGA, closed
It is greatly promoted at the ability of ampicillin and cefalexin.
Although being transformed both at home and abroad to penicillin G acylase using genetic engineering and protein engineering techniques, make its synthesis
Performance and synthesis of dynamic are greatly improved, and still, the acid resistance of mutant enzyme is also very weak, synthesizing activity is also relatively low and fixes
Changing the operational stability of enzyme also needs to further increase.Therefore, develop that a kind of acid resistance is strong, synthesizing activity is high and operational stability is good
Enzyme be of great significance.
Invention content
That the first purpose of the invention is to provide a kind of acid resistances is strong, hydrolysing activity is low, synthesizing activity is high, S/H values are high and
The good penicillin G acylase mutant of operational stability.It is in Achromobacter xylosoxidans (Achromobacter
Xylosoxidans) there is a point mutation in site following six on the basis of wild type Penicillin G acylations enzyme amino acid sequence
Or multi-point combination mutation:The 162nd amino acids sport the 24th amino acids on L, β subunit by M and sport G, β by F on α subunits
The 241st amino acids sport the 71st amino acids on Q, β subunit by N and sport the 64th bit amino on Y, β subunit by F on subunit
Acid sports the 310th amino acids on T, β subunit by A and sports V by A;
Described Achromobacter xylosoxidans (Achromobacter xylosoxidans) the wild type Penicillin G acylases
The intermediate connection peptide and 557 amino acid groups that α subunits that amino acid sequence is made of 232 amino acid, 54 amino acid form
At β subunit three parts constitute, sequence is as shown in SEQ ID NO.1.
Gradually preferred sequence is as follows for the penicillin G acylase mutant:
1, it is to have following four sites on the basis of the wild type Penicillin G of SEQ ID NO.1 is acylated enzyme amino acid sequence
In a point mutation or multi-point combination mutation:The 162nd amino acids sport the 24th bit amino on L, β subunit by M on α subunits
Acid by F sports the 241st amino acids on G, β subunit and sports the 71st amino acids on Q, β subunit by N sports Y by F.
2, it is on the basis of the wild type Penicillin G of SEQ ID NO.1 is acylated enzyme amino acid sequence to the on β subunits the 241st
Amino acids sport Q, as SPGA-1 mutant by N.
3, it is on the basis of the amino acid sequence of SPGA-1 just like next point mutation or two point mutation or three point groups
Close mutation:The 162nd amino acids sport the 24th amino acids on L, β subunit by M and are sported on G, β subunit by F on α subunits
71 amino acids sport Y by F, wherein it is preferred that on the basis of the amino acid sequence of SPGA-1 carry out three combinatorial mutagenesis, obtain
4 combination mutant SPGA-2 of enzyme amino acid sequence are acylated to wild type Penicillin G.
4, it is that T is sported by A to the 64th amino acids on β subunits on the basis of the amino acid sequence of SPGA-2, the mutation
Body is SPGA-3A mutant.Either on the basis of the amino acid sequence of SPGA-2 to the 310th amino acids on β subunits by A
V is sported, which is SPGA-3B mutant.
5, it is most preferably that T is sported by A to the 64th amino acids on β subunits on the basis of the amino acid sequence of SPGA-2,
V is sported to the 310th amino acids on β subunits by A to obtain wild type Penicillin G and be acylated 6 points of enzyme amino acid sequence and combine to dash forward
Variant, as SPGA-4, sequence such as SEQ ID NO:Shown in 3.
Second object of the present invention is to provide the nucleotide sequence of above-mentioned penicillin G acylase mutant, is following
It is any:
1) nucleotide sequence of any one of above-mentioned penicillin G acylase mutant;
Any one of 1) 2) there is penicillin G acylase with the nucleotide sequence hybridization and coding limited under strict conditions
The nucleotide sequence of active protein;
Any one of 1) or 2) 3) there is 90% or more homology with the gene order limited and encodes with benzyl penicillin
The nucleotide sequence of the protein of acylase activity.
The preparation method of the mutant penicillin G acylases of the present invention, includes the following steps:
A) by the Achromobacter xylosoxidans (Achromobacter with SEQ ID NO.2 in sequence table
Xylosoxidans) wild type Penicillin G acylases carry out saturation mutation, iteration saturation mutation and random mutation and etc. obtain
Encode the gene order of the mutant of any of the above-described kind of penicillin G acylase;
B) mutant gene sequence is inserted into plasmid and obtains expression vector;
C) expression vector conversion is entered in bacterial strain and obtains recombination engineering bacteria;
D) recombination engineering bacteria is induced with lactose and is fermented to obtain penicillin G acylase.
The preparation method of mutant penicillin G acylases of the present invention further includes further purification step, pure
Change step be will produce penicillin G acylase recombinant bacterium broken, centrifugation, collect after by immobilization metal chelating affinity chromatography into
Row purifying obtains the pure enzyme of penicillin G acylase.
Further, further include enzyme immobilizatio step, immobilization step is that above-mentioned enzyme solution after purification is used phosphate
Buffer solution (pH 8.0,0.1mol/L) dissolves, and activated treated the carriers of 50g is then added, under the conditions of 25 DEG C, 120rpm
Stirring at low speed immobilization 48h, gained immobilised enzymes is cleaned 3~5 times repeatedly with deionized water, immobilization to obtain the final product after vacuum is filtered dry
Enzyme finished product.
Further, fixation support is epoxy base carrier ECEP or amino carrier ECHA/S.
Further, plasmid is pET28b (+), and bacterial strain is E.coli BL21 (DE3).
Third object of the present invention is to provide the mutant immobilised enzymes of above-mentioned penicillin G acylase to prepare Ah not
Application in XiLin.
The application is specially:Using the penicillin G acylase mutant immobilised enzymes of the present invention as catalyst, using 10
DEG C or 20 DEG C of solid process catalyze and synthesize Amoxicillin, wherein the direct solids of substrate 6-APA and D-HPM feed intake without dissolving, process
In reaction controlling, reaction pH is without control, it is only necessary to 10 DEG C or 20 DEG C of controlling reaction temperature.
Advantage of the present invention:
The present invention combines half design and rational and orthogenesis for pinpointing saturation mutation technology by CAD
Enzyme engineering renovation technique is acylated the benzyl penicillin in the source Achromobacter xylosoxidans (Achromobacterxylosoxidans)
Enzyme is mutated, and obtains that hydrolysis vigor is lower, and synthesis of dynamic is more preferable, synthesis hydrolysis ratio (S/H) higher, acid resistance it is stronger and
The better penicillin G acylase mutant of stability, can be more effective, rapidly catalyzes and synthesizes Amoxicillin.
Other than objects, features and advantages described above, the present invention also has other objects, features and advantages.
Below with reference to accompanying drawings, the present invention is described in further detail.
Description of the drawings
The attached drawing constituted part of this application is used to provide further understanding of the present invention, schematic reality of the invention
Example and its explanation are applied for explaining the present invention, is not constituted improper limitations of the present invention.In the accompanying drawings:
Fig. 1 is that the SPGA in the embodiment of the present invention catalyzes and synthesizes Amoxicillin schematic diagram;
Fig. 2 is the SPGA protein three-dimensional structure figures in the embodiment of the present invention;
Fig. 3 is SPGA-Amoxicillin complex structure figures in the embodiment of the present invention;
Fig. 4 is the SDS-PAGE collection of illustrative plates of the preferred embodiment of the present invention;
Fig. 5 is the HPLC figures that SPGA in the embodiment of the present invention 4 catalyzes and synthesizes Amoxicillin, specially mutant SPGA-4
The HPLC figures of immobilized enzyme catalysis 6-APA and D-HPM synthesis Amoxicillin.
Specific implementation mode
Embodiment
1, the method used in following embodiments is conventional method unless otherwise specified, such as《Molecular Cloning: A Laboratory refers to
South》(J. Pehanorm Brookers, D.W. Russells write, and Huang Peitang, Wang Jiaxi, Zhu Houchu are waited and translated.3rd edition, Beijing:Scientific publication
Society, 2002) method described in carries out.Mutant primer and sequence are the limited public affairs of calm and peaceful Yongchang (Changsha) biotechnology
Department completes.E. coli host bacteria is that E.coli BL21 (DE3) are purchased from Merck companies, and e. coli host bacteria can also be
E.coli BL21 (DE3) plys, is purchased from Tiangeng company, and prokaryotic expression carrier pET28b (+) is purchased from Merck companies.DNA inscribes
Enzyme Dpn I are purchased from Fermentas companies.Autopotentiometric titrator is purchased from Wan Tong companies of Switzerland, and 8 series of model is purchased from Mei Te
Le-support benefit company, remaining material is commercially available.Meanwhile the amino acid in the present invention without illustrate it is outer with its abbreviation or
Code name is indicated (amino acid Chinese and English title and its abbreviation and code name are shown in Table 1).
1 amino acid Chinese and English title of table and its abbreviation and code name
Chinese | English name | Abbreviation | Code name | Chinese | English name | Abbreviation | Code name |
Alanine | Alanine | Ala | A | Proline | Proline | Pro | P |
Arginine | Arginine | Arg | R | Leucine | Leucine | Leu | L |
Asparagine | Asparagine | Asn | N | Isoleucine | Isoleucine | Ile | I |
Aspartic acid | Aspartic acid | Asp | D | Glycine | Glycine | Gly | G |
Cysteine | Cysteine | Cys | C | Phenylalanine | Phenylalanine | Phe | F |
Glutamine | Glutamine | Gln | Q | Methionine | Methionine | Met | M |
Glutamic acid | Glutamicacid | Glu | E | Lysine | Lysine | Lys | K |
Threonine | Threonine | Thr | T | Histidine | Histidine | His | H |
Tryptophan | Tryptophan | Trp | W | Valine | Valine | Val | V |
Serine | Serine | Ser | S | Tyrosine | Tyrosine | Tyr | Y |
The mutant penicillin G acyls that hydrolysing activity is low in order to obtain, synthesizing activity is high, acid resistance is strong and operational stability is good
Change enzyme, the wild type Penicillin G acylases that the present invention uses are derived from Achromobacter xylosoxidans
(Achromobacterxylosoxidans), according to Cai Gang, (doctoral thesis, Shanghai Inst. of Life Science, CAS are planted
Object physiological ecological research institute) with acid tolerance well, (pH5.0 keeps 85% work to research discovery wild type PGA
Power), there is good thermal stability (60 DEG C keep stablize) and preferable synthesis performance, while wild type PGA encoding genes
Sequence by successful clone to pET28b (+) prokaryotic expression carrier and be transferred to E.coli BL21 (DE3) formed recombinant expression
Genetic engineering bacterium (the present inventor is named as SPGA-WT), the recombination engineering bacteria is by Chinese Academy of Sciences's Shanghai school of life and health sciences
Friendship is given.
The amino acid sequence and nucleotide sequence of Achromobacter xylosoxidans wild type Penicillin G acylases are shown in SEQ ID
NO:1 and SEQ ID NO:2.
Achromobacter xylosoxidans wild type Penicillin G is acylated enzyme amino acid sequence explanation:
MAQPVAQAAGQESAAVAAPAQGAAGKVTIRRDAHGMPHVYADTVYGIFYGYGYAVAQDRLFQMEMARRSTQGRVAEV
LGASMVAFDKSIRGNFSPERIQRQLAALPAADRQVLDGYAAGMNAWLARIRAQPGQLMPKEFNDLGFAPADWTAYDV
AMIFIGTMANRFSDANSEIDNLALLTALKDRHGEAEAMRIFNQLRWLTDSRAPTTVPPQEGSYQPAVFQPEGAEQLA
Y
SNMWIVGRDHAKDARSILLNGPQFGWWNPAYTYGIGLHGAGFDVVGNTPFAYPSILFGHNAHVAWGSTAGFGDDVDI
YAEKLDPADRNRYFHDGQWKTLEKRTDLILVKDAAPVTLDVYRSVHGLIVKFDDAQHVAYAKARAWEGFELQSLMAW
TRKTQSANWEQWKTQAARHALTINWYYADDRGNIGYAHTGFYPRRRPGHDPRLPVPGTGEMDWLGLLPFSTNPQVYN
PGQGFIANWNNQPMRGYPSTDLFAIVWGQADRYAEIETRLKAMTANGGKVSPQQMWDLIRTTSYADVNRRHFLPFLQ
RAVQGLPADDPRVRLVAGLGGWDGMMTSEREPGYYDNAGPAVMDAWLRAMLKRTLADEMPADFFKWYSATGYPTPQA
PATGSLNLTTGVKVLFNALAGPAAGVPQRYDFFNGARADDVILAALDDALAALRQAYGKDPAAWKIPAPPMVFAPKN
FLGVPQADAKAVLSYPATQNRGTENNMTVFDGKSVRAVDVVAPGQSGFVAPDGTPSPHTRDQFDLYNSFGSKRVWFT
ADEVRRNATSEETLRYRR
The complete polypeptide chain of the gene code is by α subunits (232 amino acid), intermediate connection peptide (54 amino
Acid --- overstriking underscore part) and β subunits (557 amino acid) three parts composition.Centre connection peptide adds after protein translation
It is automatically removed between duration, obtains the penicillin G acylase with enzymatic activity being made of α subunits and β subunits.In α subunits
Middle amino acid is numbered as A1-A232, and amino acid is numbered as B1 to B557 in β subunits.
2, the detection of penicillin G acylase enzyme activity and S/H values
(1) penicillin G acylase hydrolysis vigour-testing method (titration)
Principle:Benzyl penicillin is converted to 6-APA and phenylacetic acid under penicillin G acylase effect, in NaOH solution and benzene
Acetic acid calculates penicillin G acylase vigor according to the consumption of NaOH.
Concrete operation method:It is previously added bead in 1.5ml centrifuge tubes, when bead reaches centrifuge tube scale
Stop at 1.0ml, the penicillin G acylase in accurate measuring 0.5ml Examples 1 to 4 is in frequency of oscillation in centrifuge tube
After vibrating 10min on the MS3 oscillators of 1500/min, by sample together with bead (immobilised enzymes 0.05g), add to
In the reactor of the 1% potassium penicillin G substrate solution equipped with the 30ml for being preheated to 25 DEG C, 25 DEG C of constant temperature water bath is adjusted, is used
Start timing when the sodium hydroxide titration liquid tune pH to 8.00 of 0.1mol/L, it is that 8.00 condition is stirred to react 5 minutes to keep pH,
The consumption of sodium hydroxide titration liquid is detected with autopotentiometric titrator.
Enzyme activity unit (U) is defined as:At 25 DEG C, under the conditions of pH8.0,1 μ of substrate benzyl penicillin generation is catalyzed in 1min
Required enzyme amount is 1U when mol phenylacetic acids.
(2) penicillin G acylase synthesis of dynamic assay method (HPLC methods)
The accurate liquid enzyme for weighing 0.25g immobilised enzymes or measuring 0.5ml, is added and contains 1g 6-APA and 1.25g D-
In the 50ml phosphate buffers of HPM (0.1mol/L, pH6.30), pH to 6.3 is reconciled and with above-mentioned phosphate buffer constant volume
To 100ml, at 25 DEG C, 20min is reacted with 0.1mol/l sodium hydroxide titration liquid perseverances pH6.3, records NaOH solution consumer
Product, reaction finishes filters at once, takes 0.5mL filtrates to be settled to 100mL with mobile phase and carries out HPLC detections.
Pillar:Diamosil C185μm 4.6×250mm
Mobile phase:6.8g potassium dihydrogen phosphates are weighed, after adding the ultrapure water dissolutions of 956ml, with the NaOH solution liquid tune of 1mol/L
PH to 5.8 adds 44ml chromatographic grade acetonitriles, degassing 20min or so after the water system membrane filtration in 0.22 μm of aperture.
Detection:UV 225nm
Sample size:20μL
Titer:Precision weighs the Amoxicillins 40mg standard items flowing phased soln and is settled to 200ml, and sampling carries out
HPLC is detected.
Enzyme activity calculates
Enzyme activity unit (U) is defined as:Under certain reaction condition, the unit enzyme amount A Moxi per minute for generating 1 μm of ol
Woods is 1U.
W is marked:Amoxicillin standard items weigh, mg;
P is marked:Amoxicillin standard items content, %;
A samples:Amoxicillin area in sample HPLC detections;
M:Amoxicillin molecular weight;
T:Reaction time, min;
V:Liquid enzyme sampling amount, ml;
W:Immobilised enzymes sample weighting amount, g;
m:Immobilised enzymes moisture, %.
(3) detection method of synthesis hydrolysis ratio (S/H values)
Reagent configuration, reaction condition and method are as shown in above-mentioned penicillin G acylase synthesis of dynamic assay method, reaction
It finishes and filters at once, take 0.5mL filtrates to be settled to 100mL with mobile phase and carry out HPLC detections, record the molar consumption of 6-APA
With D-pHPG (D-HPG) mole production quantity.
The production quantity (μm ol) of consumption (μm ol)/D-HPG of S/H values=6-APA
Embodiment 1:The preparation of low in hydrolysis vigor, high synthesis of dynamic SPGA mutant
By Fig. 1 reaction equations it is found that SPGA can either be catalyzed parent nucleus 6-amino-penicillanic acid (6-APA) with side chain D- to hydroxyl
Phenylglycine methyl ester (D-HPM) synthetic product Amoxicillin, but energy hydrolysate generates parent nucleus and side chain, the invertibity of the reaction
Size is decided by the equilibrium constant of the reaction;Meanwhile to be hydrolyzed into para hydroxybenzene by SPGA again sweet for p-hydroxyphenylglycine methyl ester
Therefore propylhomoserin reduces the hydrolysis vigor of SPGA, improve its synthesis of dynamic and have great importance.
1-1 determines mutational site using the method for computer simulation
1-1-1 SPGA three dimensional joint elements
Utilize the blueness of the Escherichia coli (E.coli) and the source Bacillus foecalis alkaligenes (A.faecalis) that have measured three-dimensional structure
Mycin G acylases are template, pass through SWISS-MODEL (http://swissmodel.expasy.org) online homologous modeling is soft
Part models the penicillin G acylase in Achromobacter xylosoxidans source, is energy-optimised, marking and assessment, modeling are completed
The penicillin G acylase protein three-dimensional structure in Achromobacter xylosoxidans source afterwards is as shown in Figure 2.
The foundation of 1-1-2 SPGA-Amoxicillin complex structures and the determination in mutational site
SPGA protein three-dimensional structures model and Amoxicillin are divided using molecular docking software Autodock4.0
Son docking, is carried out at the same time energy minimization and obtains SPGA-Amoxicillin complexs, the complex structure after optimization is shown in Fig. 3.
By Fig. 3's as a result, we select the points of the A162 near substrate binding pocket, B24 points, B71 points and B241 points for
Pinpoint saturation mutation site.
1-2 SPGA mutant pinpoints the structure in saturation mutation library
In order to reduce the hydrolysis vigor of wild type SPGA, improves it and synthesize the vigor of Amoxicillin, the present inventor is with SPGA-
WT is template, select on the α subunits near its substrate binding pocket the 162nd (A162 points), the 24th (B24 points) on β subunits,
The 241st (B241 points) is fixed point saturation mutation site on (B71 points) and β subunits the 71st on β subunits, passes through full plasmid PCR
Method structure fixed point saturation mutation library.Wherein respectively fixed point saturation mutation primer is as follows:
A162 point saturation mutation primers
P1:ATCGGCACCGCGAACCGCTTCTCTGACG (being saturation mutation site at underscore) (N be A or T or
C or G, K are G or T)
P2:GCGGTTCGCGGTGCCGATGAAGATCAT (being saturation mutation site at underscore) (N be A or T or
C or G, M are A or C)
B24 point saturation mutation primers
P3:GGCCCGCAG(N is A or T or C to GGCTGGTGGAATCCGGCC (being saturation mutation site at underscore)
Or G, K are G or T)
P4:CCACCAGCCCTGCGGGCCGTTCAGCAG (being saturation mutation site at underscore) (N be A or T or
C or G, M are A or C)
B71 point saturation mutation primers
P5:ACCGCGGGC(N is A or T or C to GGCGACGATGTCGACATC (being saturation mutation site at underscore)
Or G, K are G or T)
P6:ATCGTCGCCGCCCGCGGTCGAGCCCCA (being saturation mutation site at underscore) (N be A or T or
C or G, M are A or C)
B241 point saturation mutation primers
P7:GCCAACTGG(N is A or T or C to AACCAGCCGATGCGCGGC (being saturation mutation site at underscore)
Or G, K are G or T)
P8:CGGCTGGTTCCAGTTGGCGATGAACCC (being saturation mutation site at underscore) (N be A or T or
C or G, M are A or C)
Specific fixed point saturation mutation library constructing method is as follows:
Using SPGA-WT as template, using above-mentioned P1/P2, P3/P4, P5/P6 and P7/P8 as mutant primer, with full plasmid
Round pcr carries out fixed point saturation mutation respectively to this 4 points, the KOD-Plus-Neo high-fidelity DNA polymerases used in wherein PCR
And corresponding PCR buffer solutions, Mg2+, dNTPs solution buy in TOYOBO companies, and with reference to its specification carry out PCR reaction systems
Configuration and PCR reaction conditions setting.
1-3 SPGA mutant pinpoints the screening in saturation mutation library
96 mutant clon are selected respectively to above-mentioned each mutant library and carry out preliminary screening, specially:It will be all prominent
Varitron, which is inoculated in the 150ml shaking flasks of the culture mediums of LB containing 20ml, carries out fermentation and Fiber differentiation, is collected by centrifugation after 24 hours thin
Born of the same parents, ultrasonication are simultaneously collected by centrifugation supernatant and obtain crude enzyme liquid, and by titration measuring, it hydrolyzes vigor, is measured by HPLC methods
Its synthesis of dynamic;It will hydrolyze that vigor is low, the high muton of synthesis of dynamic carries out secondary screening choosing, specially:Above-mentioned muton is inoculated with
(each muton is inoculated with 3 shaking flasks) carries out fermentation and Fiber differentiation in the 500ml shaking flasks of the culture mediums of LB containing 100ml, and surveys
Fixed its hydrolyzes vigor and synthesis of dynamic, the good muton of effect be sequenced it is spare, specific each SPGA mutation vitality of subject and
Mutating acid is as shown in table 2.
2 SPGA of table mutation vitality of subject and mutating acid
Enzyme | Hydrolysis vigor (U/ml) | Synthesis of dynamic (U/ml) |
SPGA-WT | 26 | 4 |
Mα162L | 22 | 7.3 |
Fβ24G | 16 | 6 |
Fβ71Y | 20 | 7 |
Nβ241Q | 16 | 7.5 |
The preparation of 1-4 low in hydrolysis vigor, high synthesis of dynamic SPGA multipoint mutation bodies
As seen from the results in Table 2, N β 241Q mutant has lower hydrolysis vigor relative to wild type and other mutant
With higher synthesis of dynamic, be named as SPGA-1, in order to obtain the better SPGA mutant of effect, the present inventor with
SPGA-1 is template, respectively by M α 162L, F β 24G and F β 71Y with full plasmid pcr carry out fixed point saturation mutation be superimposed into
On SPGA-1, double mutant, three point mutation and four point mutation are formed, are lived by the hydrolysis vigor and synthesis that measure each mutant
Power chooses step experiment under the progress of best results, and specific each SPGA mutation vitality of subject and mutating acid are as shown in table 3.
3 SPGA of table mutation vitality of subject and mutating acid
As shown in Table 3, wherein four point mutation bodies (M α 162L, F β 24G, N β 241Q and F β 71Y) effect is best, and is ordered
Entitled SPGA-2.
Embodiment 2:The preparation of acid resistance SPGA mutant
Since enzymatic clarification Amoxicillin carries out under condition of acidic pH, simultaneously because in industrial processes, it is green
Mycin G acylases need continuous use 5 to 10 days, and this requires the enzymes to keep stabilization and not easy in inactivation under condition of acidic pH,
And the acid resistance of wild type Penicillin G acylases is poor, therefore it is badly in need of a kind of novel PGA of tolerance acid pH of exploitation.To understand
Certainly this problem in industrial production, the present inventor set new exploitation route, the SPGA-2 mutant best to said effect
Further it is transformed.
The structure of 2-1 acid resistance SPGA random mutant libraries
In order to improve the acid resistance of SPGA, the present inventor is T7 universal primers (SEQ ID with SPGA-2 templates, wherein primer
NO:13 and 14), a random mutant libraries are built by the method for fallibility PCR, and by adjusting fallibility PCR reaction systems
Middle Mg2+And Mn2+Concentration and dCTP and dTTP oligonucleotides concentration, it is only thousand points to make the base mispairing rate of the mutant library
Two, that is, ensure that a mutant only has 1 to 2 amino acid and mutates.The detailed process for building mutant library is as follows.
Fallibility PCR reaction systems:
Fallibility PCR reaction conditions are:First 95 DEG C of pre-degeneration 5min;Then 94 DEG C denaturation 30s, 56 DEG C annealing 1min, 72 DEG C
Extend 1.5min, totally 25 cycles;Last 72 DEG C of extensions 10min.
Fallibility PCR product obtained above is subjected to electrophoresis and gel extraction purifying, by product and protokaryon table after purification
NdeI and Xho I double digestions are carried out respectively up to carrier pET28b (+), and digestion carries out gel extraction in 3 hours respectively, by recovery product
According to product:Carrier is 3:1 molar ratio is mixed, and T4DNA ligase are added in 16 DEG C of connections overnight.Second day, lead to
The method for crossing chemical conversion, which is transferred in e. coli bl21 (DE3), builds engineering bacteria, you can obtains big random of a storage capacity
Mutant library.
It is prepared by the high flux screening and mutant of 2-2 acid resistance SPGA mutant libraries
With the toothpick after high-temperature sterilization, the single bacterium colony in careful picking mutant library is inoculated in 96 equipped with LB culture mediums
In porocyte culture plates, wherein LB culture volumes are for 200 holes μ L/ and containing the kanamycins of 50 μ g/ml, in 37 DEG C,
It is cultivated in the constant-temperature table of 250rmp 8 hours, 1% lactose, 25 DEG C, Fiber differentiation 8 hours in the constant-temperature table of 250rmp.
After induction, 96 porocyte culture plates are put into 2 hours of freeze thawing in -86 DEG C of ultra low temperature freezer, taking-up is positioned over room temperature
Middle half an hour is placed in 96 porocyte culture plates centrifuges and is centrifuged 20 minutes in 4,000rmp, 4 DEG C.In above-mentioned enzyme solution,
By 1:0.05mol/L is added in 2 volume ratios, and the phosphate buffer of pH 3.0 incubates 1 hour in 25 DEG C.
According to the high-throughput screening method in 103667418 A of Chinese patent application CN, sieved from above-mentioned mutant library
About 20000 clones have been selected, have obtained 10 color changes obviously and the muton of numeric ratio SPGA-2 high.Then prominent to this 10
Varitron carries out secondary screening, and detailed process is:This 10 mutons are inoculated in the 500ml shaking flasks of the culture mediums of LB containing 100ml and are carried out
Fermentation and induction, and its hydrolysis and synthesis of dynamic are measured by titration and HPLC methods, obtain 2 mutation better than control effect
Son is respectively designated as PGA-3A and PGA-3B, shows that PGA-3A has occurred in the 64th site amino acids of β subunits by sequencing result
Change, T has been mutated by A, and PGA-3B is changed in the 310th site amino acids of β subunits, and V has been mutated by A.
In order to further obtain the better SPGA mutation of acid resistance pH, the present inventor dashes forward above-mentioned A β 64T and A β 310V
Variant is overlapped, and measures its hydrolysis vigor and synthesis of dynamic, by the six point mutation body (M α 162L, F β 24G, N β 241Q, F β
71Y, A β 64T and A β 310V) it is named as SPGA-4.Specific each acid resistance SPGA amino acid mutations point and mutation vitality of subject such as table
Shown in 4.
4 acid resistance SPGA amino acid mutations point of table and mutation vitality of subject
Embodiment 3 recombinate SPGA albumen isolate and purify and immobilization
3-1 recombination SPGA albumen isolates and purifies
Due to introducing 2 of N-terminal and C-terminal in prokaryotic expression carrier pET28b (+) during expression vector establishment
His-tag, therefore, the present inventor are carried out using the histidine tagImmobilization metal chelates affinity chromatography (IMAC)To purify weight
Histone, the specific method is as follows.
SPGA zymotic fluids after taking 100mL to induce overnight, abandoned after centrifugation supernatant collect thalline (10000rpm, 4 DEG C,
10min), with phosphate buffer (pH 8.0,0.1mol/L), twice, thalline were collected by centrifugation for washing thalline repeatedly, concentrates 5 times of weights
It is suspended from 20ml phosphate buffers (pH 8.0,0.1mol/L).Treated bacterium solution is placed in ice water and carries out ultrasound
It is crushed until clarification, ultrasonication condition therein are:Work 2s, is spaced 5s.Above-mentioned broken lysate is placed in low temperature
(12,000rpm, 4 DEG C, 20min) is centrifuged in supercentrifuge, collects supernatant, recombination SPGA albumen is obtained, by the big and heavy group of egg
White sample introduction is to having activated and in conjunction with Ni+IDA resins on, carry out gradient elution with the imidazoles of gradient concentration, utilize protein chromatographic
System (Bio-Rad) is monitored in real time, and when occurring stable protein peak in computer, starting collection, disappearance is until the peak
Only.
Recombination zymoprotein, which is sealed in after isolating and purifying in sterile bag, is positioned over 4 DEG C of refrigerators in case subsequent experimental, simultaneously
To this, zymoprotein carries out purity analysis with SDS-PAGE protein electrophoresis after purification, as a result sees Fig. 4.As seen from the figure, recombination SPGA
It is made of two subunits of α, β, size respectively may be about 28kD and 63kD.
3-2 recombinates the immobilization of SPGA albumen
A, the activation of fixation support
Glutaraldehyde 30ml, the dipotassium hydrogen phosphate (K of accurate measurement 60%2HPO4·3H2O) 4.76g be dissolved in 600ml go from
In sub- water, it finally is settled to 1000ml with deionized water, while it is 8.0 to adjust its PH with phosphoric acid solution, it is spare after sterilizing;By ring
Oxygroup carrier ECEP or amino carrier ECHA/S (Italian ResindionS.r.l companies) 250g are put into above-mentioned solution, and
2h is activated in 25 DEG C of stirring at low speed, carrier is collected by filtration, vacuum is filtered dry standby after being used in combination aseptic deionized water to rinse 2~3 times repeatedly
With.
B, enzyme immobilizatio
A certain amount of above-mentioned enzyme solution after purification is taken, is dissolved with phosphate buffer (pH 8.0,0.1mol/L), is then added
50g is activated treated carrier, the stirring at low speed immobilization 48h under the conditions of 25 DEG C, 120rpm spend gained immobilised enzymes
Ionized water cleans 3~5 times repeatedly, and vacuum is filtered dry rear up to immobilised enzymes finished product.It is accurate weigh the above-mentioned immobilised enzymes of 1g (with
For SPGA-WT) vigor and synthesizing activity measurement is hydrolyzed, using ECEP and ECHA/S as the immobilized enzyme hydrolysis enzyme activity of carrier
Respectively 262U/g and 239U/g, synthesizing activity are respectively 45U/g and 34U/g, and epoxy base carrier ECEP immobilized enzymes are bright
It is aobvious to be higher than amino carrier ECHA/S immobilised enzymes, therefore select epoxy base carrier ECEP as the fixation support of SPGA.
The property of 4 mutant SPGA-4 immobilised enzymes of embodiment and its application for preparing Amoxicillin
The property of 4-1 mutant SPGA-4 immobilised enzymes
Protein purification, immobilization are carried out to above-mentioned wild type and saltant type SPGA according to the method for embodiment 4, meanwhile, point
Not Ce Ding immobilised enzymes hydrolysis and synthesis of dynamic and S/H values, mutant SPGA-4 immobilised enzymes and other muton immobilizations
The Nature comparison of enzyme is shown in Table 5.
5 wild type of table and saltant type SPGA immobilised enzymes Nature comparisons
Enzyme | Hydrolysis vigor (U/g) | Synthesis of dynamic (U/g) | S/H values |
SPGA-WT | 262 | 45 | 2.1 |
SPGA-1 | 169 | 73 | 4.3 |
SPGA-2 | 101 | 142 | 10.8 |
SPGA-3A | 79 | 153 | 13.4 |
SPGA-3B | 68 | 169 | 14.7 |
SPGA-4 | 30 | 212 | 16.8 |
As shown in Table 5, mutant SPGA-4 immobilised enzymes declines relative to wild type SPGA immobilised enzymes, hydrolysis vigor
8.7 times, synthesis of dynamic improves 5.6 times, and S/H values improve 8 times, illustrate the mutant immobilised enzymes relative to wild type
SPGA immobilised enzymes has better Amoxicillin synthesis performance, not facile hydrolysis side chain and product Amoxicillin.
4-2 mutant SPGA-4 immobilised enzymes acid resistances are tested
By above-mentioned wild type and saltant type SPGA immobilised enzymes, it is respectively placed in identical enzyme amount (200U synthesis of dynamic)
In the buffer solution of pH2.0, pH3.0, pH4.0, pH5.0, pH6.0 and pH7.0,1 hour is incubated in 25 DEG C, takes out immobilization afterwards
Enzyme is rinsed 4~5 times repeatedly with aseptic deionized water, and to ensure to incite somebody to action there is no buffer solution residual in immobilised enzymes, treated consolidates
Surely change enzyme and measure its remaining vigor with HPLC methods, concrete outcome is as shown in table 6.
6 wild type of table and saltant type SPGA immobilised enzymes acid pH tolerances compare
According to 6 result of table it is found that SPGA-4 immobilised enzymes also keeps about 80% vigor under the conditions of pH2.0, in pH3.0
Under the conditions of keep 86% vigor, under the conditions of 7.0 pH4.0-activity do not change substantially, show the enzyme in acid condition
It keeps stablizing.
4-3 mutant SPGA-4 immobilised enzymes prepares the application of Amoxicillin
(1) 10 DEG C of solid process
210ml is preheated to 10 DEG C of pure water in advance to pour into equipped with 2000U mutant SPGA-4 immobilised enzymes (with wild type
SPGA immobilised enzymes be control) beaker in, 21.0g6-APA the and 18.3g D-HPM solids for being directly added into accurate weighing (rub
You are than being 1:1.04) to reaction system, stirring is opened, 10 DEG C of reactions are maintained;In conversion process, 10 DEG C of controlling reaction temperature,
PH is not required to.
Endpoint:When declining 0.02 after pH value peaks, you can terminate reaction.
(2) 20 DEG C of solid process
230ml is preheated to 20 DEG C of pure water in advance to pour into equipped with 1800U mutant SPGA-4 immobilised enzymes (with wild type
SPGA immobilised enzymes is control) beaker in, 20.0g6-APA the and 17.09g D-HPM solids of accurate weighing are added without molten
Solve (molar ratio 1:1.02) to reaction system, stirring is opened, 20 DEG C of reactions are maintained;In conversion process, controlling reaction temperature
20 DEG C, pH is not required to.
Endpoint:When declining 0.02 after pH value peaks, you can terminate reaction.
(3) Amoxicillin crystallization reaction
After reaction terminating, washing, which filters out immobilised enzymes and washs filtering repeatedly with reaction mother liquor, is collected into whole A Moxi
Woods coarse powder quickly dissolves Amoxicillin with 6mol/L hydrochloric acid tune pH, is filtered to remove insoluble impurities, and growing the grain about 5 minutes slowly adds
Enter 6mol/L ammonium hydroxide tune pH value to 5.0 ± 0.1, is cooled to 1~4 DEG C, growing the grain about 20min, powder collected by filtration.It is taken out with vacuum
Dry be placed in drier is dried overnight, after pack of weighing, detection Amoxicillin moisture, content and 6-APA and D-HPM conversions
Rate prepares the HPLC collection of illustrative plates of Amoxicillin synthesis referring to Fig. 5, specific experiment correction data using mutant SPGA-4 immobilised enzymes
It is shown in Table 7.
7 wild type SPGA of table and saltant type SPGA-4 immobilised enzymes Transformation Application Experimental comparisons
Enzyme | Reaction temperature (DEG C) | Reaction time (min) | Conversion ratio |
SPGA-WT | 10 | 120 | 87.3% |
SPGA-4 | 10 | 80 | 99.2% |
SPGA-WT | 20 | 105 | 89.2% |
SPGA-4 | 20 | 60 | 99.3% |
As shown in Table 7, mutant SPGA-4 immobilised enzymes reaction 6-APA and D-HPM conversion ratio up to 99% with
On, the reaction of Amoxicillin is synthesized under same reaction condition with wild type SPGA immobilized enzyme catalysis, 6-APA and D-HPM's
Conversion ratio is not achieved 90%.
4-4 mutant SPGA-4 immobilised enzymes operational stability batches are tested
In order to preferably reflect that the stability of the mutant, the present inventor during the experiment set its reaction condition such as
Under:The total throwing amount of SPGA-4 immobilised enzymes (212U/g) is 8000U, and substrate 6-APA and D-HPM solid molar ratio is 1:1.02 instead
PH is answered to be not required to, reaction temperature is 20 DEG C, and reaction volume 1000ml, the results are shown in Table 8 for specific experiment.
8 mutant SPGA-4 immobilised enzymes operational stability batches of table are tested
By the experiment of SPGA-4 immobilised enzymes operational stability batches it is found that SPGA-4 immobilised enzymes warp prepared by the present invention
Continuous 300 batch transformation experiment is crossed, the reaction time is not obviously prolonged, and immobilized enzyme is not decreased obviously, and is shown
Mutant SPGA-4 immobilised enzymes prepared by the present invention has good operational stability.
Each mutant SPGA of the present invention can also be applied to prepare ammonia benzyl west other than it can be applied to synthesis Amoxicillin
The semi-synthetic beta-lactam antibiotic such as woods, cefalexin, cefadroxil, Cefaclor and Cefradine;The present invention simultaneously
Do not limited by above-mentioned specific verbal description, the present invention can in the range of claims are summarized essence according to the present invention
God does various changes.These changes are all within the scope of the present invention.
Claims (4)
1. penicillin G acylase mutant, which is characterized in that it is in Achromobacter xylosoxidans(Achromobacter xylosoxidans)Wild type Penicillin G has following arbitrary mutation on the basis of being acylated enzyme amino acid sequence:
1)The 241st amino acids sport Q by N on β subunits;
2)The 162nd amino acids sport the 241st amino acids on L and β subunits by M and sport Q by N on α subunits;
3)The 24th amino acids sport the 241st amino acids on G and β subunits by F and sport Q by N on β subunits;
4)The 71st amino acids sport the 241st amino acids on Y and β subunits by F and sport Q by N on β subunits;
5)The 162nd amino acids sport the 241st amino acids on L, β subunit by M and are sported on Q and β subunits by N on α subunits
24th amino acids sport G by F;
6)The 162nd amino acids sport the 241st amino acids on L, β subunit by M and are sported on Q and β subunits by N on α subunits
71st amino acids sport Y by F;
7)The 162nd amino acids sport the 24th amino acids on L, β subunit by M and are sported on G, β subunit by F on α subunits
241 amino acids sport the 71st amino acids on Q and β subunits by N and sport Y by F;
8)The 162nd amino acids sport the 24th amino acids on L, β subunit by M and are sported on G, β subunit by F on α subunits
241 amino acids sport on Q, β subunit the 71st amino acids by N and sport on Y and β subunits the 310th amino acids by A by F
Sport V;
9)The 162nd amino acids sport the 24th amino acids on L, β subunit by M and are sported on G, β subunit by F on α subunits
241 amino acids by N sport the 71st amino acids on Q, β subunit and sport the 64th amino acids on Y and β subunits by F is dashed forward by A
Become T;
10)The 162nd amino acids sport the 24th amino acids on L, β subunit by M and are sported on G, β subunit by F on α subunits
241 amino acids by N sport the 71st amino acids on Q, β subunit and sport the 310th amino acids on Y, β subunit by F is dashed forward by A
Become the 64th amino acids on V and β subunits and T is sported by A;
The Achromobacter xylosoxidans wild type Penicillin G is acylated the α that enzyme amino acid sequence is made of 232 amino acid
The β subunit three parts of intermediate connection peptide and 557 amino acid compositions that subunit, 54 amino acid form are constituted, sequence such as SEQ
Shown in ID NO.1.
2. encoding the gene of mutant described in claim 1.
3. application of the penicillin G acylase mutant described in claim 1 in preparing Amoxicillin.
4. application of the penicillin G acylase mutant according to claim 3 in preparing Amoxicillin, feature exist
In, specifically using penicillin G acylase mutant immobilised enzymes as catalyst, using 10 DEG C or 20 DEG C of solid process catalyze and synthesize Ah
Amdinocillin, wherein substrate 6-amino-penicillanic acid and the direct solid of D-pHPG feed intake, and pH is not necessarily in reaction process
Control, it is only necessary to which controlling reaction temperature is 10 DEG C or 20 DEG C;
The penicillin G acylase mutant is in Achromobacter xylosoxidans wild type Penicillin G acylase amino acid
There is following mutation in sequence basis:The 162nd amino acids sport the 24th amino acids on L, β subunit by M and are dashed forward by F on α subunits
Become the 241st amino acids on G, β subunit and sport the 71st amino acids on Q, β subunit by N being sported on Y, β subunit by F
310 amino acids sport the 64th amino acids on V and β subunits by A and sport T by A.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510736957.7A CN105274082B (en) | 2015-11-03 | 2015-11-03 | A kind of synthesis penicillin G acylase mutant and its application in preparing Amoxicillin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510736957.7A CN105274082B (en) | 2015-11-03 | 2015-11-03 | A kind of synthesis penicillin G acylase mutant and its application in preparing Amoxicillin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105274082A CN105274082A (en) | 2016-01-27 |
CN105274082B true CN105274082B (en) | 2018-08-31 |
Family
ID=55143916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510736957.7A Active CN105274082B (en) | 2015-11-03 | 2015-11-03 | A kind of synthesis penicillin G acylase mutant and its application in preparing Amoxicillin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105274082B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105483105B (en) * | 2016-02-23 | 2018-08-31 | 上海星维生物技术有限公司 | A kind of penicillin G acylase mutant |
CN105567777A (en) * | 2016-03-07 | 2016-05-11 | 内蒙古常盛制药有限公司 | Method for recycling amoxicillin mother solution |
KR101985911B1 (en) * | 2017-12-28 | 2019-06-04 | 아미코젠주식회사 | Mutants of penicillin G acylase from Achromobacter sp. CCM 4824, and uses thereof |
CN109161540B (en) * | 2018-09-28 | 2021-03-19 | 湖南福来格生物技术有限公司 | Penicillin V acylase mutant, coding sequence, recombinant expression vector, genetic engineering bacterium and application |
CN111500564B (en) * | 2020-06-02 | 2022-01-18 | 南京工业大学 | Penicillin G acylase mutant and application thereof in enzymatic synthesis of cefamandole |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103184182B (en) * | 2013-04-11 | 2015-02-11 | 南京工业大学 | Penicillin acylase, as well as high-yield strain and application thereof |
CN104789510A (en) * | 2015-05-06 | 2015-07-22 | 南京工业大学 | Penicillin acylase as well as encoding gene, producing strain and application thereof |
-
2015
- 2015-11-03 CN CN201510736957.7A patent/CN105274082B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN105274082A (en) | 2016-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105274082B (en) | A kind of synthesis penicillin G acylase mutant and its application in preparing Amoxicillin | |
CN111172140B (en) | Nitrilase mutant and application thereof in preparation of anti-epileptic drug intermediate | |
CN109750009A (en) | A kind of glufosinate-ammonium dehydrogenase mutant and its application | |
CN105543201B (en) | A kind of Cephalosporin C acylase mutant | |
CN105087533B (en) | A kind of mutant of penicillin G acylase and its preparation method and application | |
CN103865911B (en) | Penicillin G acylase mutant and the application in synthesis cephalosporin analog antibiotic thereof | |
CN102277338A (en) | Diketoreductase mutant and application thereof | |
CN101165190B (en) | Preparation for N-acetylneuraminic acid by immobilization double-enzyme method | |
CN108546698A (en) | A kind of aspartic acid enzyme mutant | |
CN109735559B (en) | Biological preparation method of gamma-aminobutyric acid | |
CN109609478B (en) | α -transaminase and mutant thereof and application thereof in asymmetric synthesis of L-glufosinate-ammonium | |
CN104152505A (en) | Method for transforming and preparing 4-hydroxyl-L-isoleucine by using recombinant bacterial strains | |
CN105624128B (en) | Immobilized monoamine oxidase and application thereof in synthesis of chiral azabicyclo compound | |
CN105018443B (en) | A kind of epoxide hydrolase mutant and preparation method thereof | |
CN113481189B (en) | Sucrose isomerase mutant and application thereof | |
CN113584008B (en) | Penicillin G acylase mutant and application thereof | |
CN112358530B (en) | Polypeptide tag, highly soluble recombinant nitrilase and application of polypeptide tag and highly soluble recombinant nitrilase in synthesis of medicinal chemicals | |
CN109161540B (en) | Penicillin V acylase mutant, coding sequence, recombinant expression vector, genetic engineering bacterium and application | |
CN103966185A (en) | Double-enzyme system for efficiently synthesizing S-adenosylhomocysteine and application method thereof | |
CN111057698B (en) | L-arabinose isomerase, mutant and application thereof | |
CN111500564B (en) | Penicillin G acylase mutant and application thereof in enzymatic synthesis of cefamandole | |
CN115896076B (en) | Arginine deiminase mutant, recombinant thereof and application thereof in catalytic production of citrulline | |
CN114934037B (en) | Asparaase mutant for producing 3-aminopropionitrile | |
CN110904087B (en) | L-arabinose epimerase mutant and application thereof | |
CN115838696A (en) | Prevotella meso-diaminopimelate dehydrogenase mutant and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A synthetic penicillin G acylase mutant and its application in the preparation of amoxicillin Granted publication date: 20180831 Pledgee: Changsha Bank city branch of Limited by Share Ltd. Pledgor: HUNAN FLAG BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024980012003 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |